Genmab Combination Cuts Death Risk 50% in Phase 3 Cancer Trial
Genmab said its petosemtamab combination cut the risk of death by 50% in a Phase 3 head and neck cancer trial.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.